ZONTIVITY (vorapaxar), platelet aggregation inhibitor

• ZONTIVITY has Marketing Authorisation, in combination with acetylsalicylic acid (ASA) and where appropriate with clopidogrel, in the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (MI).
• Its actual benefit is insufficient for reimbursement by National Health Insurance because of:
• a minor clinical added value in terms of morbidity and the lack of demonstrated efficacy in terms of mortality;
• and the greater occurrence of haemorrhagic events with the therapeutic strategy vorapaxar + ASA ± clopidogrel versus the strategy ASA ± clopidogrel.

-